Podcast: Deep dive —Why Fenbendazole Cannot Reach Human Trials
Overview
Fenbendazole has never been approved for humans; it is a veterinary dewormer. To the FDA, it is closer to a new drug for human use than a “repurposed” one, so there is no existing human approval to lean on.
ClinicalTrials.gov lists no registered human trials of fenbendazole itself. The closest precedent is oxfendazole, a related compound and one of fenbendazole’s metabolites. The NIH’s Infectious Diseases Institute took it through a Phase 1 safety study, and Phase 2 trials for parasitic infections are now running.
The basic pathway
Getting to a first human dose takes a sponsor, an FDA conversation, and an accepted IND.
Find a sponsor. Someone must legally own the trial: a company, a university, or a physician acting as “sponsor-investigator.” In practice, this means a physician-researcher at an institution with an IRB (ethics board).
Hold a pre-IND meeting with the FDA. It is free and strongly recommended. You send a briefing package and ask what data the FDA needs before humans can be dosed.
File the Investigational New Drug (IND) application. It has three main parts:
Chemistry, manufacturing and controls (CMC): a human-grade product made under GMP, with defined formulation, purity, and stability data. Veterinary-grade or online-purchased fenbendazole won’t qualify.
Pharmacology and toxicology: animal safety data. Veterinary data exists, but the FDA may still want formal GLP toxicology studies at human-relevant doses and durations.
Clinical protocol: study design, dose, endpoints, eligibility, safety monitoring, and investigator qualifications.
Wait out the 30-day FDA review. With no clinical hold and IRB approval, the trial can start.
Run the trial phases. Phase 1 tests safety and dosing; Phase 2 looks for early signs of effectiveness; Phase 3 confirms in large trials.
Submit a New Drug Application (NDA). A 505(b)(2) NDA can rely partly on published literature, but helps less without an existing human approval to reference.
Real-world obstacles
Funding is the biggest barrier, followed by thin human evidence.
Money. Fenbendazole is off-patent and cheap, so no company profits from approval. A modest Phase 1 can cost $1–5 million; a full program costs far more. Funding usually comes from NIH/NCI grants or repurposing nonprofits such as Cures Within Reach or the Anticancer Fund.
Evidence. Interest in fenbendazole for cancer rests mostly on personal accounts plus cell and mouse studies. Published case reports describe liver injury in people who self-medicated, which a review board would weigh.
An easier route. Mebendazole and albendazole are related benzimidazoles already FDA-approved for humans, with similar proposed anticancer mechanisms and prior cancer trials. Starting there skips the manufacturing and human-safety hurdles.
Individual access. Right to Try only covers drugs that have completed Phase 1, so fenbendazole doesn’t qualify. A physician could request a single-patient expanded access IND, but would face the same manufacturing and safety-data questions.
Practical first steps
Find an academic investigator (often an oncologist, if cancer is the interest) who studies drug repurposing or benzimidazoles; authors of fenbendazole or mebendazole cancer papers on PubMed are a good starting list.
Approach repurposing nonprofits about funding or partnership.
Let the investigator lead the pre-IND conversation with the FDA.

